Robbins Geller Rudman & Dowd LLP and Faruqi & Faruqi, LLP reminded investors of an August 31, 2026, deadline to seek lead plaintiff status in a class-action lawsuit against Insulet Corporation. The legal action targets the period between February 2025 and May 2026.
The lawsuit alleges Insulet failed to disclose defective manufacturing controls for its Omnipod insulin delivery systems. These claims follow two voluntary Medical Device Corrections issued by the company in March and May 2026.
Insulet reported that manufacturing issues could lead to insulin under-delivery. These disclosures triggered significant drops in the company's stock price. The ongoing litigation creates uncertainty regarding future legal costs and regulatory scrutiny.